Phase II study of bevacizumab combined with oral leucovorin plus UFT for elderly patients with metastatic colorectal cancer.

ABSTRACT: Interventions: Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. UFT 300mg/m2/day and LV 75mg/body/day is administered orally for 21 days every 28 days. Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

DISEASE(S): Advanced And Recurrent Colorectal Cancer

PROVIDER: 2618974 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR